ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Teva Pays Big For Deuterium Specialist

by Rick Mullin
April 6, 2015 | APPEARED IN VOLUME 93, ISSUE 14

Teva Pharmaceuticals will acquire Auspex Pharmaceuticals, a specialist in applying deuterium chemistry, for $3.2 billion. La Jolla, Calif.-based Auspex substitutes deuterium for hydrogen in known molecules to create therapies with improved safety and efficacy. Its SD-809 (deutetrabenazine) drug candidatehas delivered positive Phase III clinical trial results as a treatment for Huntington’s disease with a pharmacokinetic profile that allows for lower doses. Auspex hopes to file a New Drug Application this year. SD-809 is also being developed to treat tardive dyskinesia and Tourette’s syndrome.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment